|
|
|
Plant - Aurangabad, Maharashtra state,
India |
|
-
Conforms to WHO standards
-
Manufactures oral and injectable finished dosages
-
Approval from MCC, South Africa
-
Main products: rifampicin, pyrazinamide, ethambutol and lisinopril
|
|
Major products
|
|
Product
|
Therapeutic area
|
API
|
Finished dosage
|
|
|
|
Oral
|
Injectable
|
|
|
|
Rifampicin |
Anti-TB |
|
|
|
|
|
Ethambutol |
Anti-TB |
|
|
|
|
|
Rifampicin
+
Isoniazid |
Anti-TB |
|
|
|
|
|
Anti-TB
combi pack |
Anti-TB |
|
|
|
|
|
|
|
|
 |
|
|
